Unit for Mycology, Statens Serum Institut, Copenhagen, Denmark.
Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
J Antimicrob Chemother. 2020 Jul 1;75(7):1807-1819. doi: 10.1093/jac/dkaa111.
Terbinafine resistance is increasingly reported in Trichophyton, rendering susceptibility testing particularly important in non-responding cases. We performed a multicentre evaluation of six EUCAST-based methods.
Ten laboratories susceptibility tested terbinafine, itraconazole, voriconazole and amorolfine against a blinded panel of 38 terbinafine WT and target gene mutant isolates. E.Def 9.3.1 modifications included: medium with/without addition of chloramphenicol and cycloheximide (CC), incubation at 25°C to 28°C for 5-7 days and three MIC endpoints [visually and spectrophotometrically (90%/50% inhibition)], generating 7829 MICs. Quality control (QC) strains were Aspergillus flavus ATCC 204304 and CNM-CM1813. Eyeball, ECOFFinder (where ECOFF stands for epidemiological cut-off) and derivatization WT upper limits (WT-ULs), very major errors (VMEs; mutants with MICs ≤WT-ULs) and major errors (MEs; WT isolates with MICs >WT-ULs) were determined.
MICs fell within the QC ranges for ATCC 204304/CNM-CM1813 for 100%/96% (voriconazole) and 84%/84% (itraconazole), respectively. Terbinafine MICs fell within 0.25-1 mg/L for 96%/92%, suggesting high reproducibility. Across the six methods, the number of terbinafine MEs varied from 2 to 4 (2.6%-5.2%) for Trichophyton rubrum and from 0 to 2 (0%-2.0%) for Trichophyton interdigitale. Modes for WT and mutant populations were at least seven 2-fold dilutions apart in all cases. Excluding one I121M/V237I T. rubrum mutant and two mixed WT/mutant T. interdigitale specimens, the numbers of VMEs were as follows: T. rubrum: CC visual, 1/67 (1.5%); CC spectrophotometric 90% inhibition, 3/59 (5.1%); and CC spectrophotometric 50% inhibition, 1/67 (1.5%); and T. interdigitale: none. Voriconazole and amorolfine MICs were quite uniform, but trailing growth complicated determination of itraconazole visual and spectrophotometric 90% inhibition MIC.
Although none of the laboratories was experienced in dermatophyte testing, error rates were low. We recommend the CC spectrophotometric 50% inhibition method and provide QC ranges and WT-ULs for WT/non-WT classification.
特比萘芬的耐药性在絮状表皮癣菌中越来越多地被报道,这使得药敏试验在非应答病例中尤为重要。我们对 6 种基于 EUCAST 的方法进行了多中心评估。
10 个实验室对特比萘芬、伊曲康唑、伏立康唑和阿莫罗芬进行了药敏试验,使用盲法对 38 个特比萘芬 WT 和靶基因突变株进行了测试。E.Def 9.3.1 的修改包括:添加/不添加氯霉素和环丝氨酸的培养基(CC)、在 25°C 至 28°C 孵育 5-7 天和三个 MIC 终点[目测和分光光度法(90%/50%抑制)],生成 7829 个 MIC。质量控制(QC)菌株为黄曲霉 ATCC 204304 和 CNM-CM1813。通过目测、ECOFFinder(ECOFF 代表流行病学截止值)和衍生 WT 上限(WT-ULs)、非常大的错误(VMEs;MICs≤WT-ULs 的突变体)和大错误(MEs;MICs>WT-ULs 的 WT 分离株)来确定 MICs 结果。
ATCC 204304/CNM-CM1813 的 QC 范围分别为 100%/96%(伏立康唑)和 84%/84%(伊曲康唑)。特比萘芬 MICs 为 0.25-1mg/L,符合率为 96%/92%,提示具有较高的重现性。在六种方法中,红色毛癣菌的特比萘芬 ME 数量从 2 到 4(2.6%-5.2%)不等,而趾间毛癣菌的 ME 数量从 0 到 2(0%-2.0%)不等。在所有情况下,WT 和突变体种群的模式至少相差 7 个 2 倍稀释度。除了 1 个红色毛癣菌 I121M/V237I 突变体和 2 个混合 WT/突变体趾间毛癣菌标本外,VME 的数量如下:红色毛癣菌:CC 目测,1/67(1.5%);CC 分光光度法 90%抑制,3/59(5.1%);CC 分光光度法 50%抑制,1/67(1.5%);趾间毛癣菌:无。伏立康唑和阿莫罗芬的 MICs 相当一致,但后续生长使伊曲康唑目测和分光光度法 90%抑制 MIC 的测定变得复杂。
尽管没有实验室在皮肤真菌检测方面有经验,但错误率较低。我们推荐 CC 分光光度法 50%抑制法,并提供 WT/非 WT 分类的 QC 范围和 WT-ULs。